GLPG vs. PRTA, SAGE, HRMY, HCM, ARWR, BPMC, RARE, MYOV, MRTX, and RVNC
Should you be buying Galapagos stock or one of its competitors? The main competitors of Galapagos include Prothena (PRTA), Sage Therapeutics (SAGE), Harmony Biosciences (HRMY), HUTCHMED (HCM), Arrowhead Pharmaceuticals (ARWR), Blueprint Medicines (BPMC), Ultragenyx Pharmaceutical (RARE), Myovant Sciences (MYOV), Mirati Therapeutics (MRTX), and Revance Therapeutics (RVNC). These companies are all part of the "pharmaceutical preparations" industry.
Galapagos vs.
Galapagos (NASDAQ:GLPG) and Prothena (NASDAQ:PRTA) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, risk, institutional ownership, analyst recommendations, earnings, dividends and community ranking.
In the previous week, Prothena had 3 more articles in the media than Galapagos. MarketBeat recorded 5 mentions for Prothena and 2 mentions for Galapagos. Galapagos' average media sentiment score of 0.02 beat Prothena's score of -0.16 indicating that Galapagos is being referred to more favorably in the media.
19.5% of Galapagos shares are held by institutional investors. Comparatively, 91.7% of Prothena shares are held by institutional investors. 2.9% of Galapagos shares are held by company insiders. Comparatively, 31.2% of Prothena shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Galapagos has a net margin of -42.15% compared to Prothena's net margin of -216.95%. Galapagos' return on equity of -5.08% beat Prothena's return on equity.
Prothena received 123 more outperform votes than Galapagos when rated by MarketBeat users. Likewise, 71.50% of users gave Prothena an outperform vote while only 66.14% of users gave Galapagos an outperform vote.
Prothena has lower revenue, but higher earnings than Galapagos. Prothena is trading at a lower price-to-earnings ratio than Galapagos, indicating that it is currently the more affordable of the two stocks.
Galapagos currently has a consensus target price of $49.17, suggesting a potential upside of 30.95%. Prothena has a consensus target price of $82.50, suggesting a potential upside of 75.27%. Given Prothena's stronger consensus rating and higher possible upside, analysts plainly believe Prothena is more favorable than Galapagos.
Galapagos has a beta of 0.31, indicating that its stock price is 69% less volatile than the S&P 500. Comparatively, Prothena has a beta of 0.41, indicating that its stock price is 59% less volatile than the S&P 500.
Summary
Prothena beats Galapagos on 12 of the 18 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding GLPG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Galapagos Competitors List
